Search

Sana Biotechnology Inc

Закрыт

СекторЗдравоохранение

3.19 1.92

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.1

Макс.

3.24

Ключевые показатели

By Trading Economics

Доход

-16M

-64M

Прибыль на акцию

-0.13

Сотрудники

142

EBITDA

-17M

-61M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+155.59% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

268M

1.2B

Предыдущая цена открытия

1.27

Предыдущая цена закрытия

3.19

Новостные настроения

By Acuity

25%

75%

34 / 339 Рейтинг в Healthcare

Sana Biotechnology Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 сент. 2026 г., 20:03 UTC

Correlated Moves

Sana Biotechnology Inc. is trading higher today, benefiting from strong market activity alongside Recursion Pharmaceuticals Inc. despite remaining below its 20-day moving average.

11 сент. 2026 г., 23:46 UTC

Sana Biotechnology Inc. shares are higher in after-market hours, despite no specific news identified. Broader market context includes recent U.S. inflation data.

10 сент. 2026 г., 20:07 UTC

News
Correlated Moves

Sana Biotechnology Inc shares are lower amid a broader biotechnology sector decline, influenced by rising Treasury yields and inflation concerns affecting market sentiment.

9 сент. 2026 г., 23:01 UTC

Sana Biotechnology Inc. shares are higher in after-market hours, recovering from earlier declines amid unclear drivers for the price movement.

8 сент. 2026 г., 20:03 UTC

News

Sana Biotechnology shares are declining despite a report on diabetes treatment advancements and a $25 million investment from Mayo Clinic.

4 сент. 2026 г., 20:07 UTC

Sana Biotechnology Inc shares are lower amid broader market pressures following a strong jobs report, with no specific company news identified.

2 сент. 2026 г., 20:08 UTC

Social Media
News

Sana Biotechnology Inc is advancing today amid gains in the Biotechnology sector and upcoming investor conferences focused on engineered cell therapies.

31 авг. 2026 г., 20:07 UTC

Sana Biotechnology Inc. shares decline today, continuing a trend since Friday's close, amid broader market pressures from rising interest rate expectations.

28 авг. 2026 г., 23:56 UTC

Sana Biotechnology Inc. shares advanced modestly higher in after-market trading, remaining near the upper end of their one-month range.

27 авг. 2026 г., 23:02 UTC

Sana Biotechnology shares declined in after-market trading, reflecting a notable drop since Thursday's close, despite earlier gains earlier in the session.

26 авг. 2026 г., 19:46 UTC

Sana Biotechnology Inc shares are higher today, trading near the upper end of their one-month range and above the 20-day moving average.

25 авг. 2026 г., 23:16 UTC

Sana Biotechnology Inc shares are lower in after-market hours. Market sentiment was affected by a sharp decline in crude oil prices.

24 авг. 2026 г., 19:36 UTC

Correlated Moves

Sana Biotechnology Inc's shares are lower today, reflecting broader declines in the biotech sector, including a drop in the ARK Genomic Revolution ETF.

21 авг. 2026 г., 23:36 UTC

Sana Biotechnology Inc. shares moved lower in after-market trading, despite resilience in major stocks like Tesla and UnitedHealth. The price remains above its 20-day moving average.

20 авг. 2026 г., 23:01 UTC

Sana Biotechnology Inc. shares are higher in after-hours trading, driven by gains in the Biotechnology sub-sector and remaining above its 20-day moving average.

19 авг. 2026 г., 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, following a notable decline from earlier highs. No specific news was identified to explain the move.

18 авг. 2026 г., 19:46 UTC

Sana Biotechnology Inc. shares are lower today, reflecting a decline since Monday amid rising Treasury yields and ongoing inflation concerns.

17 авг. 2026 г., 23:46 UTC

Sana Biotechnology Inc shares are slightly higher in after-market hours. No specific news was identified to explain the movement.

14 авг. 2026 г., 20:06 UTC

News

Sana Biotechnology shares declined amid mixed analyst ratings and broader market challenges, with BofA lowering its price target to $6.00 from $7.00.

13 авг. 2026 г., 19:36 UTC

Sana Biotechnology Inc shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

12 авг. 2026 г., 23:46 UTC

Sana Biotechnology Inc shares are lower in after-market hours, with no specific news identified to explain the price movement.

11 авг. 2026 г., 19:31 UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10 авг. 2026 г., 23:01 UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7 авг. 2026 г., 19:56 UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5 авг. 2026 г., 19:56 UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4 авг. 2026 г., 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3 авг. 2026 г., 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31 июл. 2026 г., 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30 июл. 2026 г., 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29 июл. 2026 г., 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

Сравнение c конкурентами

Изменение цены

Sana Biotechnology Inc Прогноз

Целевая цена

By TipRanks

155.59% рост

Прогноз на 12 месяцев

Средняя 8 USD  155.59%

Максимум 12 USD

Минимум 6 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Sana Biotechnology Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

34 / 339Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat